The urocortin peptides: biological relevance and laboratory aspects of UCN3 and its receptor

References

• Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 2001;98(13):7570–7575.
   PubMed Web of Science ®Google Scholar
• McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87(3):873–904.
   PubMed Web of Science ®Google Scholar
• Muglia L, Jacobson L, Dikkes P, et al. Regulation of gonadotropins by corticotropin-releasing factor and urocortin. Front Endocrinol. 2013;4:12.
   PubMedGoogle Scholar
• Neufeld-Cohen A, Evans AK, Getselter D, et al. Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry. 2010;15(4):426–441.
   PubMed Web of Science ®Google Scholar
• Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001;7(5):605–611.
   PubMed Web of Science ®Google Scholar
• Squillacioti C, Pelagalli A, Liguori G, et al. Urocortins in the mammalian endocrine system. Acta Vet Scand. 2019;61(1):46.
   PubMed Web of Science ®Google Scholar
• Kuperman Y, Issler O, Regev L, et al. Perifornical urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis. Proc Natl Acad Sci USA. 2010;107(18):8393–8398. 4
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Richards AM. Urocortins: actions in health and heart failure. Clin Chim Acta. 2017;474:76–87.
   PubMed Web of Science ®Google Scholar
• Grammatopoulos DK. Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br J Pharmacol. 2012;166(1):85–97.
   PubMed Web of Science ®Google Scholar
• Grace CR, Perrin MH, Cantle JP, et al. Common and divergent structural features of a series of corticotropin releasing factor-related peptides. J Am Chem Soc. 2007;129(51):16102–16114.
   PubMed Web of Science ®Google Scholar
• Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001;15(10):1678–1693.
   PubMed Web of Science ®Google Scholar
• Grammatopoulos DK, Chrousos P. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab. 2002;13(10):436–444.
   PubMed Web of Science ®Google Scholar
• Pisarchik A, Slominski AT. Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J. 2001;15(14):2754–2756.
   PubMedGoogle Scholar
• Sakai K, Yamada M, Horiba N, et al. The genomic organization of the human corticotropin-releasing factor type-1 receptor. Gene. 1998;219(1–2):125–130.
   PubMed Web of Science ®Google Scholar
• Catalano RD, Kyriakou T, Chen J, et al. Regulation of corticotropin-releasing hormone type 2 receptors by multiple promoters and alternative splicing: identification of multiple splice variants. Mol Endocrinol. 2003;17(3):395–410.
   PubMedGoogle Scholar
• Valdenaire O, Giller T, Breu V, et al. A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. Biochim Biophys Acta. 1997;1352(2):129–132.
   PubMedGoogle Scholar
• Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA. 2001;98(5):2843–2848.
   PubMed Web of Science ®Google Scholar
• Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378(6554):287–292.
   PubMed Web of Science ®Google Scholar
• Li C, Vaughan J, Sawchenko PE, et al. Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci. 2002;22(3):991–1001.
   PubMed Web of Science ®Google Scholar
• Pan W, Kastin AJ. Urocortin and the brain. Prog Neurobiol. 2008;84(2):148–156.
   PubMed Web of Science ®Google Scholar
• Wittmann G, Füzesi T, Liposits Z, et al. Distribution and axonal projections of neurons coexpressing thyrotropin-releasing hormone and urocortin 3 in the rat brain. J Comp Neurol. 2009;517(6):825–840.
   PubMed Web of Science ®Google Scholar
• Deussing JM, Breu J, Kühne C, et al. Urocortin 3 modulates social discrimination abilities via corticotropin-releasing hormone receptor type 2. J Neurosci. 2010;30(27):9103–9116.
   PubMed Web of Science ®Google Scholar
• Venihaki M, Sakihara S, Subramanian S, et al. Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol. 2004;16(5):411–422.
   PubMed Web of Science ®Google Scholar
• Chen P, Lin D, Giesler J, et al. Identification of urocortin 3 afferent projection to the ventromedial nucleus of the hypothalamus in rat brain. J Comp Neurol. 2011;519(10):2023–2042.
   PubMed Web of Science ®Google Scholar
• Koob GF, Heinrichs SC. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 1999;848(1–2):141–152.
   PubMed Web of Science ®Google Scholar
• De Fanti BA, Martínez JA. Central urocortin activation of sympathetic-regulated energy metabolism in Wistar rats. Brain Res. 2002;930(1-2):37–41.
   PubMed Web of Science ®Google Scholar
• Chalmers DT, Lovenberg TW, De Souza EB. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci. 1995;15(10):6340–6350.
   PubMed Web of Science ®Google Scholar
• Van Pett K, Viau V, Bittencourt JC, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol. 2000;428(2):191–212.
   PubMed Web of Science ®Google Scholar
• McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1998;338(3):171–179.
   PubMed Web of Science ®Google Scholar
• Neufeld-Cohen A, Kelly PA, Paul ED, et al. Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge. Biol Psychiatry. 2012;72(6):437–447.
   PubMed Web of Science ®Google Scholar
• Dhabhar FS, McEwen BS. Acute stress enhances while chronic stress suppresses cell-mediated immunity in vivo: a potential role for leukocyte trafficking. Brain Behav Immun. 1997;11(4):286–306.
   PubMed Web of Science ®Google Scholar
• Selye H. Stress without distress. In: Serban G, editor. Psychopathology of human adaptation. Boston (MA): Springer; 1976. p. 137–146.
   Google Scholar
• Henckens MJAG, Deussing JM, Chen A. Region-specific roles of the corticotropin-releasing factor-urocortin system in stress. Nat Rev Neurosci. 2016;17(10):636–651.
   PubMed Web of Science ®Google Scholar
• Saffran M, Schally AV, Benfey BG. Stimulation of the release of corticotropin from the adenohypophysis by a neurohypophysial factor. Endocrinology. 1955;57(4):439–444.
   PubMed Web of Science ®Google Scholar
• Van Den Eede F, Van Broeckhoven C, Claes SJ. Corticotropin-releasing factor-binding protein, stress and major depression. Ageing Res Rev. 2005;4(2):213–239.
   PubMed Web of Science ®Google Scholar
• Shemesh Y, Forkosh O, Mahn M, et al. Ucn3 and CRF-R2 in the medial amygdala regulate complex social dynamics. Nat Neurosci. 2016;19(11):1489–1496.
   PubMed Web of Science ®Google Scholar
• Ohata H, Shibasaki T. Effects of urocortin 2 and 3 on motor activity and food intake in rats. Peptide. 2004;25(10):1703–1709.
   PubMed Web of Science ®Google Scholar
• Pelleymounter MA, Joppa M, Ling N, et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides. 2004;25(4):659–666.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Telegdy G. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice. Brain Res Bull. 2008;75(5):509–512.
   PubMed Web of Science ®Google Scholar
• Todorovic C, Sherrin T, Pitts M, et al. Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice. Neuropsychopharmacology. 2009;34(6):1416–1426.
   PubMed Web of Science ®Google Scholar
• Bale TL, Giordano FJ, Vale WW. A new role for corticotropin-releasing factor receptor-2: suppression of vascularization. Trends Cardiovasc Med. 2003;13(2):68–71.
   PubMed Web of Science ®Google Scholar
• Bosch OJ, Dabrowska J, Modi ME, et al. Oxytocin in the nucleus accumbens shell reverses CRFR2-evoked passive stress-coping after partner loss in monogamous male prairie voles. Psychoneuroendocrinology. 2016;64:66–78.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Adams DH, Simen A, et al. Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci. 2007;27(48):13329–13340.
   PubMed Web of Science ®Google Scholar
• Bagosi Z, Palotai M, Simon B, et al. Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice. Brain Res. 2016;1652:21–29.
   PubMed Web of Science ®Google Scholar
• Bisson JI, Cosgrove S, Lewis C, et al. Post-traumatic stress disorder. BMJ. 2015;351:h6161. doi 1136/bmj.h6161.
   PubMed Web of Science ®Google Scholar
• Richardson LK, Frueh BC, Acierno R. Prevalence estimates of combat-related post-traumatic stress disorder: critical review. Aust N Z J Psychiatry. 2010;44(1):4–19.
   PubMed Web of Science ®Google Scholar
• Ishitobi Y, Nakayama S, Yamaguchi K, et al. Association of CRHR1 and CRHR2 with major depressive disorder and panic disorder in a Japanese population. Am J Med Genet. 2013;162(1):78–78.
   Google Scholar
• De Luca V, Tharmalingam S, Kennedy JL. Association study between the corticotropin-releasing hormone receptor 2 gene and suicidality in bipolar disorder. Eur Psychiatry. 2007;22(5):282–287.
   PubMed Web of Science ®Google Scholar
• Papiol S, Arias B, Gastó C, et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104(1–3):83–90.
   PubMed Web of Science ®Google Scholar
• Wong ML, Dong C, Maestre-Mesa J, et al. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry. 2008;13(8):800–812.
   PubMed Web of Science ®Google Scholar
• Wolf EJ, Mitchell KS, Logue MW, et al. Corticotropin releasing hormone receptor 2 (CRHR-2) gene is associated with decreased risk and severity of posttraumatic stress disorder in women. Depress Anxiety. 2013;30(12):1161–1169.
   PubMed Web of Science ®Google Scholar
• Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687–698.
   PubMed Web of Science ®Google Scholar
• Kritikou I, Basta M, Vgontzas AN, et al. Sleep apnoea and the hypothalamic-pituitary-adrenal axis in men and women: effects of continuous positive airway pressure. Eur Respir J. 2016;47(2):531–540.
   PubMed Web of Science ®Google Scholar
• Ma S, Mifflin SW, Cunningham JT, et al. Chronic intermittent hypoxia sensitizes acute hypothalamic-pituitary-adrenal stress reactivity and fos induction in the rat locus coeruleus in response to subsequent immobilization stress. Neuroscience. 2008;154(4):1639–1647.
   PubMed Web of Science ®Google Scholar
• Endeshaw Y, Rice TB, Schwartz AV, et al. Snoring, daytime sleepiness, and incident cardiovascular disease in the health, aging, and body composition study. Sleep. 2013;36(11):1737–1745.
   PubMed Web of Science ®Google Scholar
• Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc. 2008;5(2):207–217.
   PubMedGoogle Scholar
• Ishman SL, Yang CJ, Cohen AP, et al. Is the OSA-18 predictive of obstructive sleep apnea: comparison to polysomnography. Laryngoscope. 2015;125(6):1491–1495.
   PubMed Web of Science ®Google Scholar
• Kundel V, Shah N. Impact of portable sleep testing. Sleep Med Clin. 2017;12(1):137–147.
   PubMed Web of Science ®Google Scholar
• Ferrarini A, Rupérez FJ, Erazo M, et al. Fingerprinting‐based metabolomic approach with LC‐MS to sleep apnea and hypopnea syndrome: a pilot study. Metabolomics. 2013;34(19):2873–2881.
   Google Scholar
• Ząbek A, Stanimirova I, Deja S, et al. Fusion of the 1H NMR data of serum, urine and exhaled breath condensate in order to discriminate chronic obstructive pulmonary disease and obstructive sleep apnea syndrome. Metabolomics. 2015;11(6):1563–1574.
   PubMed Web of Science ®Google Scholar
• Xu XL, Zhu RZ, Sharma M, et al. The influence of social media on sleep quality: a study of undergraduate students in Chongqing, China. J Nurs Care. 2015;4:253.
   Google Scholar
• Xu X, Lin Q, Zhang Y, et al. Influence of WeChat on sleep quality among undergraduates in Chongqing, China: a cross-sectional study. SpringerPlus. 2016;5(1):2066.
   PubMedGoogle Scholar
• Gozal D, Jortani S, Snow AB, et al. Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in pediatric obstructive sleep apnea. Am J Respir Crit Care Med. 2009;180(12):1253–1261.
   PubMed Web of Science ®Google Scholar
• Turner AI, Smyth N, Hall SJ, et al. Psychological stress reactivity and future health and disease outcomes: a systematic review of prospective evidence. Psychoneuroendocrinology. 2020;114:104599.
   PubMed Web of Science ®Google Scholar
• Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2018;184:131–144.
   PubMed Web of Science ®Google Scholar
• Rosmond R, Björntorp P. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J Intern Med. 2000;247(2):188–197.
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Charles CJ, Espiner EA, et al. Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J. 2005;26(19):2046–2054.
   PubMed Web of Science ®Google Scholar
• Patel K, Rademaker MT, Kirkpatrick CM, et al. Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep. Br J Pharmacol. 2012;166(6):1916–1925.
   PubMed Web of Science ®Google Scholar
• Chanalaris A, Lawrence KM, Stephanou A, et al. Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol. 2003;35(10):1295–1305.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Totsune K, Murakami O, et al. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab. 2004;89(4):1897–1903.
   PubMed Web of Science ®Google Scholar
• Brar BK, Railson J, Stephanou A, et al. Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol. 2002;172(2):283–293.
   PubMed Web of Science ®Google Scholar
• Brar BK, Jonassen AK, Egorina EM, et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004;145(1):24–35.
   PubMed Web of Science ®Google Scholar
• Chanalaris A, Lawrence KM, Townsend PA, et al. Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun. 2005;328(2):442–448.
   PubMed Web of Science ®Google Scholar
• Onorati F, Chen-Scarabelli C, Knight R, et al. Targeting urocortin signaling pathways to enhance cardioprotection: is it time to move from bench to bedside? Cardiovasc Drugs Ther. 2013;27(5):451–463.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kawabe K, Sapru HN. Cardiovascular responses to microinjections of urocortin 3 into the nucleus tractus solitarius of the rat. Am J Physiol Heart Circ Physiol. 2009;296(2):H325–H332.
   PubMed Web of Science ®Google Scholar
• Venkatasubramanian S, Griffiths ME, McLean SG, et al. Vascular effects of urocortins 2 and 3 in healthy volunteers. JAHA. 2013;2(1):e004267.
   Google Scholar
• Stirrat CG, Venkatasubramanian S, Pawade T, et al. Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. Br J Clin Pharmacol. 2016;82(4):974–982.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Ponikowski P, et al. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. Eur J Heart Fail. 2013;15(6):679–689.
   PubMed Web of Science ®Google Scholar
• Giamouridis D, Gao MH, Lai NC, et al. Urocortin 3 gene transfer increases function of the failing murine heart. Hum Gene Ther. 2019;30(1):10–20.
   PubMed Web of Science ®Google Scholar
• Giamouridis D, Gao MH, Lai NC, et al. Effects of urocortin 2 versus urocortin 3 gene transfer on left ventricular function and glucose disposal. JACC Basic Transl Sci. 2018;3(2):249–264.
   PubMedGoogle Scholar
• Novembri R, Carrarelli P, Toti P, et al. Urocortin 2 and urocortin 3 in endometriosis: evidence for a possible role in inflammatory response. Mol Hum Reprod. 2011;17(9):587–593.
   PubMed Web of Science ®Google Scholar
• Novembri R, Torricelli M, Bloise E, et al. Effects of urocortin 2 and urocortin 3 on IL-10 and TNF-α expression and secretion from human trophoblast explants. Placenta. 2011;32(12):969–974.
   PubMed Web of Science ®Google Scholar
• You X, Chen Z, Sun Q, et al. Urocortins exhibit differential effects on PGE2 and PGF2α output via CRHR2 in human myometrium. Reproduction. 2021;162(1):11–20.
   PubMed Web of Science ®Google Scholar
• Kavalakatt S, Khadir A, Madhu D, et al. Urocortin 3 overexpression reduces ER stress and heat shock response in 3T3-L1 adipocytes. Sci Rep. 2021;11(1):15666.
   PubMed Web of Science ®Google Scholar
• Keleş E, Gebeşçe A, Turan F, et al. Utility of the pediatric sleep questionnaire and urocortin level in urine as screening tools in pediatric patients with suspected obstructive sleep apnea syndrome. Iran J Public Health. 2016;45(6):828–829.
   PubMed Web of Science ®Google Scholar
• Xu H, Zheng X, Qian Y, et al. Metabolomics profiling for obstructive sleep apnea and simple snorers. Sci Rep. 2016;6:30958.
   PubMed Web of Science ®Google Scholar
• Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry. 2010;15(6):574–588.
   PubMed Web of Science ®Google Scholar
• Ushikai M, Asakawa A, Sakoguchi T, et al. Centrally administered urocortin 3 inhibits food intake and gastric emptying in mice. Endocrine. 2011;39(2):113–117.
   PubMed Web of Science ®Google Scholar
• Terashi M, Asakawa A, Cheng KC, et al. Effects of peripherally administered urocortin 3 on feeding behavior and gastric emptying in mice. Exp Ther Med. 2011;2(2):333–335.
   PubMed Web of Science ®Google Scholar
• Sharpe AL, Phillips TJ. Central urocortin 3 administration decreases limited-access ethanol intake in nondependent mice. Behav Pharmacol. 2009;20(4):346–351.
   PubMed Web of Science ®Google Scholar
• Li C, Chen P, Vaughan J, et al. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA. 2007;104(10):4206–4211.
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Cameron VA, Charles CJ, et al. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J. 2006;17:2088–2098.
   Google Scholar
• Faraj Tabrizi P, Mohebbi Tafrechi A, Peters I, et al. Cancer-specific loss of urocortin 3 in human renal cancer. Adv Ther. 2020;37(1):288–299.
   PubMed Web of Science ®Google Scholar
• Kavalakatt S, Khadir A, Madhu D, et al. Urocortin 3 levels are impaired in overweight humans with and without type 2 diabetes and modulated by exercise. Front Endocrinol. 2019;10:762.
   PubMed Web of Science ®Google Scholar
• Dermitzaki E, Liapakis G, Androulidaki A, et al. Corticotrophin-releasing factor (CRF) and the urocortins are potent regulators of the inflammatory phenotype of human and mouse white adipocytes and the differentiation of mouse 3T3L1 pre-adipocytes. PLOS One. 2014;9(5):e97060.
   PubMed Web of Science ®Google Scholar
• Rhee SH, Ma EL, Lee Y, et al. Corticotropin releasing hormone and urocortin 3 stimulate vascular endothelial growth factor expression through the cAMP/CREB pathway. J Biol Chem. 2015;290(43):26194–26203.
   PubMed Web of Science ®Google Scholar
• CLIA compliant analytical method validation plan and template. Association of Public Health Laboratories; 2013. p. 1–14. Available from: https://www.aphl.org/aboutAPHL/publications/Documents/EH_2013Dec_CLIA-Compliant-LRN-C-Method-Validation-Template.pdf
   Google Scholar
• Sun Q, Welsh KJ, Bruns DE, et al. Inadequate reporting of analytical characteristics of biomarkers used in clinical research: a threat to interpretation and replication of study findings. Clin Chem. 2019;65(12):1554–1562.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218–228.
   PubMed Web of Science ®Google Scholar
• Groenwold RH, Van Deursen AM, Hoes AW, et al. Poor quality of reporting confounding bias in observational intervention studies: a systematic review. Ann Epidemiol. 2008;18(10):746–751.
   PubMed Web of Science ®Google Scholar
• Casals M, Girabent-Farrés M, Carrasco JL. Methodological quality and reporting of generalized linear mixed models in clinical medicine (2000–2012): a systematic review. PLOS One. 2014;9(11):e112653.
   PubMed Web of Science ®Google Scholar
• Li C, Chen P, Vaughan J, et al. Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology. 2003;144(7):3216–3224.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Totsune K, Saruta M, et al. Expression of urocortin 3/stresscopin in human adrenal glands and adrenal tumors. Peptides. 2006;27(1):178–182.
   PubMed Web of Science ®Google Scholar
• Pepels PP, Spaanderman ME, Bulten J, et al. Placental urocortins and CRF in late gestation. Placenta. 2009;30(6):483–490.
   PubMed Web of Science ®Google Scholar
• Pepels PP, Spaanderman ME, Hermus AR, et al. Placental urocortin-2 and -3: endocrine or paracrine functioning during healthy pregnancy? Placenta. 2010;31(6):475–481.
   PubMed Web of Science ®Google Scholar
• Temur M, Yilmaz Ö, Aksun S, et al. Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(3):218–222.
   PubMed Web of Science ®Google Scholar
• Liew OW, Yandle TG, Chong JP, et al. High-Sensitivity sandwich ELISA for plasma NT-proUcn2: plasma concentrations and relationship to mortality in heart failure. Clin Chem. 2016;62(6):856–865.
   PubMed Web of Science ®Google Scholar
• Alarslan P, Unal Kocabas G, Demir I, et al. Increased urocortin 3 levels are associated with the risk of having type 2 diabetes mellitus. J Diabetes. 2020;12(6):474–482.
   PubMed Web of Science ®Google Scholar